Breaking News Instant updates and real-time market news.

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27

Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD

Galapagos NV (GLPG) and MorphoSys (MPSYY) announced the presentation of more detailed results of the Phase 1 study with the investigational IL-17C antibody MOR106 in atopic dermatitis patients at the American Academy of Dermatology Annual Meeting 2018. Initial study data were reported in September 2017. In the study, MOR106 showed first signs of activity and durable responses and was generally well tolerated in AD patients. In the multiple ascending doses part, 25 patients received four infusions once weekly of either MOR106 or placebo in a 3:1 ratio. Patients were followed for 10 weeks after the end of the treatment period. In the MAD part in AD patients reported at AAD 2018, all adverse drug reactions observed were mild-to-moderate and transient in nature. No serious adverse events and no infusion-related reactions were recorded. MOR106 exhibited a favorable pharmacokinetics profile with dose-dependent exposure. At the highest dose level of MOR106, in 83% of patients an improvement of at least 50% in signs and extent of AD, as measured by EASI-50, was recorded at week 4. The onset of activity occurred within two to four weeks, depending on the dose administered. MOR106 was generated using MorphoSys' Ylanthia antibody platform and is based on a target discovered by Galapagos. IL-17C is a cytokine which has been related to dermal inflammation and has been shown to be distinct from other members of the IL-17 cytokine family. MOR106 is the first publically known human monoclonal antibody against IL-17C in clinical development worldwide. MOR106 is an investigational drug and its safety and efficacy are yet to be established. It is expected that Phase 2 development with MOR106 will be initiated in the first half of 2018.

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

GLPG Galapagos NV
$115.33

-1.4 (-1.20%)

09/15/17
STFL
09/15/17
NO CHANGE
Target $120
STFL
Buy
Galapagos NV price target raised to $120 from $101 at Stifel
After hosting a call with two key opinion leaders on idiopathic pulmonary fibrosis, Stifel analyst Adam Walsh noted that the physicians expressed the view that the efficacy of GLPG1690 in the Phase 2 FLORA trial "was as good as one could have hoped for." As a result of the positive physician feedback, he increased his probability of success for '1690 to 15% from 10% and raised his price target on Galapagos to $120 from $101. Walsh keeps a Buy rating on Galapagos shares.
01/03/18
JEFF
01/03/18
NO CHANGE
Target $185
JEFF
Buy
Vertex competitor's cystic fibrosis update unsurprising, says Jefferies
Jefferies analyst Michael Yee says last night's cystic fibrosis update from Vertex Pharmaceuticals (VRTX) competitor Galapagos NV (GLPG) contained no surprises. None of Galapagos' developments are unexpected, and 2018 remains a period where the Vertex competitor is running a number of "proof of concept" studies to see if it has something, Yee tells investors in a research note. He believes challenges remain for cystic fibrosis competitors because making a triple requires three individual drugs to show minimal drug-drug interactions and have a clean side effect profile. Yee keeps a Buy rating on Vertex with a $185 price target.
02/01/18
DBAB
02/01/18
NO CHANGE
Target $193
DBAB
Buy
Vertex investors should pay more attention to Galapagos, says Deutsche Bank
Deutsche Bank analyst Navin Jacob raised his price target for Vertex Pharmaceuticals (VRTX) to $193 from $175 following last night's Q4 results and keeps a Buy rating on the shares. The triple efficacy data are better than expected, and create a "very high hurdle" for competitors, Jacob tells investors in a research note. He believes, however, that Vertex investors should be paying more attention to Galapagos NV (GLPG). Galapagos CEO Ono van de Stolpe has "100% confidence" that the company will be getting its first novel triple combo into patients in Q1, Jacob tells investors in a research note after meeting with the executive. The analyst expects some volatility to Vertex shares if Galapagos is able to start the triple trial in Q1. Jacob, however, adds that his math puts Galapagos two-and-a-half years behind Vertex and that the efficacy hurdle is "VERY high."
02/13/18
HCWC
02/13/18
NO CHANGE
Target $107
HCWC
Neutral
Vertex halted trials in France as protest, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein says he learned via Twitter and a news article that Vertex Pharmaceuticals (VRTX) decided to discontinue the Phase 3 trials of its triple combination therapy for cystic fibrosis in France due to an inability to reach reimbursement agreement with the French authorities for Orkambi. Releasing patients may inadvertently help Vertex's competitors gain ground, especially Galapagos (GLPG) and Proteostasis (PTI), Fein tells investors in a research note. He keeps a Neutral rating on Vertex shares with a $103 price target.
MPSYY MorphoSys
$46.29

1.29 (2.87%)

10/06/17
JPMS
10/06/17
UPGRADE
JPMS
Overweight
MorphoSys upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded MorphoSys to Overweight and raised his price target for the shares EUR 85 from EUR 62. The analyst believes the company's pipeline optionality is not reflected in the current valuation.
10/06/17
10/06/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Anadarko (APC) upgraded to Overweight from Neutral at Atlantic Equities. 2. La Quinta (LQ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jeffrey Donnelly saying he believes the spin-off of La Quinta's real estate to a newly formed REIT in 2018 will lead to the sale of the brand/management to a larger brand company. 3. Kraft Heinz (KHC) upgraded to Overweight from Neutral at Piper Jaffray with analyst Michael Lavery saying he expects the company to make further acquisitions. 4. MorphoSys (MPSYY) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying he believes the company's pipeline optionality is not reflected in the current valuation. 5. Motorola Solutions (MSI) upgraded to Buy from Neutral at Cleveland Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

UGP

Ultrapar

$11.42

0.375 (3.40%)

09:33
07/23/18
07/23
09:33
07/23/18
09:33
Downgrade
Ultrapar rating change  »

Ultrapar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZZ

Cosan

$8.32

0.105 (1.28%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Downgrade
Cosan rating change  »

Cosan downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

, CYH

Community Health

$2.72

-0.055 (-1.99%)

09:32
07/23/18
07/23
09:32
07/23/18
09:32
Recommendations
LifePoint, Community Health, Apollo Global, HCA Healthcare analyst commentary  »

Deal activity could pick…

LPNT

LifePoint

$47.85

-0.75 (-1.54%)

CYH

Community Health

$2.72

-0.055 (-1.99%)

APO

Apollo Global

$35.39

-0.22 (-0.62%)

HCA

HCA Healthcare

$108.01

0.31 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 27

    Jul

  • 27

    Jul

  • 02

    Aug

  • 22

    Aug

BIDU

Baidu

$260.00

-2.32 (-0.88%)

09:31
07/23/18
07/23
09:31
07/23/18
09:31
Downgrade
Baidu rating change  »

Baidu downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

SLM

Sallie Mae

$11.71

-0.11 (-0.93%)

, CHGG

Chegg

$29.07

-0.07 (-0.24%)

09:31
07/23/18
07/23
09:31
07/23/18
09:31
Hot Stocks
Sallie Mae, Chegg introduce enhanced Study Starter benefit »

Sallie Mae (SLM) and…

SLM

Sallie Mae

$11.71

-0.11 (-0.93%)

CHGG

Chegg

$29.07

-0.07 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

09:30
07/23/18
07/23
09:30
07/23/18
09:30
Hot Stocks
Trump calls U.S. Post Office Amazon's 'delivery boy' at fraction of cost »

President Trump tweeted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

HAL

Halliburton

$45.23

0.26 (0.58%)

09:29
07/23/18
07/23
09:29
07/23/18
09:29
Hot Stocks
Halliburton says sees international business better in 2H18 »

Says seeing ramp up in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BV

BrightView

$21.95

0.14 (0.64%)

09:29
07/23/18
07/23
09:29
07/23/18
09:29
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:28
07/23/18
07/23
09:28
07/23/18
09:28
Hot Stocks
Halliburton says sees Q3 effective tax rate approximately 20% »

Says expects go generate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BSX

Boston Scientific

$33.77

0.06 (0.18%)

, SYK

Stryker

$174.33

1.44 (0.83%)

09:26
07/23/18
07/23
09:26
07/23/18
09:26
Recommendations
Boston Scientific, Stryker analyst commentary  »

Boston Scientific price…

BSX

Boston Scientific

$33.77

0.06 (0.18%)

SYK

Stryker

$174.33

1.44 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 14

    Aug

  • 15

    Aug

HAS

Hasbro

$94.02

0.38 (0.41%)

09:26
07/23/18
07/23
09:26
07/23/18
09:26
Hot Stocks
Hasbro says 30% of manufacturing is outside of China »

Says biggest percentage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

BV

BrightView

$21.95

0.14 (0.64%)

09:23
07/23/18
07/23
09:23
07/23/18
09:23
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

09:22
07/23/18
07/23
09:22
07/23/18
09:22
Periodicals
VW board member wary of 'humiliating' Audi's Stadler, FT reports »

Hiltrud Werner, a top…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$33.77

0.06 (0.18%)

09:21
07/23/18
07/23
09:21
07/23/18
09:21
Recommendations
Boston Scientific analyst commentary  »

Boston Scientific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 14

    Aug

  • 15

    Aug

HAL

Halliburton

$45.23

0.26 (0.58%)

09:21
07/23/18
07/23
09:21
07/23/18
09:21
Earnings
Halliburton says sees Q3 earnings 'similar' to Q2 »

Says temporary challenges…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

09:20
07/23/18
07/23
09:20
07/23/18
09:20
General news
U.S. Sentiment Strength Extends into July: »

U.S. Sentiment Strength…

MU

Micron

$55.01

-1.2 (-2.13%)

, QCOM

Qualcomm

$58.62

-0.7 (-1.18%)

09:19
07/23/18
07/23
09:19
07/23/18
09:19
Recommendations
Micron, Qualcomm, AMD, Intel, Nvidia, Microchip, Texas Instruments, Marvell, Analog Devices, Cypress Semiconductor analyst commentary  »

Tariff uncertainty a…

MU

Micron

$55.01

-1.2 (-2.13%)

QCOM

Qualcomm

$58.62

-0.7 (-1.18%)

AMD

AMD

$16.49

-0.22 (-1.32%)

INTC

Intel

$51.92

-0.09 (-0.17%)

NVDA

Nvidia

$250.87

-1.15 (-0.46%)

MCHP

Microchip

$94.39

-0.46 (-0.48%)

TXN

Texas Instruments

$114.99

0.34 (0.30%)

MRVL

Marvell

$21.85

0.14 (0.64%)

ADI

Analog Devices

$97.81

-0.46 (-0.47%)

CY

Cypress Semiconductor

$17.06

-0.09 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 07

    Aug

  • 14

    Aug

  • 16

    Aug

HAL

Halliburton

$45.23

0.26 (0.58%)

09:18
07/23/18
07/23
09:18
07/23/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

HAL

Halliburton

$45.23

0.26 (0.58%)

09:18
07/23/18
07/23
09:18
07/23/18
09:18
Hot Stocks
Breaking Hot Stocks news story on Halliburton »

Halliburton says sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
07/23/18
07/23
09:18
07/23/18
09:18
Options
Overnight activity included 89 trades in SPX and 3 trades in VIX »

89 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$45.23

0.26 (0.58%)

09:17
07/23/18
07/23
09:17
07/23/18
09:17
Hot Stocks
Halliburton says expects international markets to improve in coming quarters »

Says "better…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

MSFT

Microsoft

$106.29

1.59 (1.52%)

09:16
07/23/18
07/23
09:16
07/23/18
09:16
Conference/Events
Microsoft to hold a summit »

Microsoft Business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

HAL

Halliburton

$45.23

0.26 (0.58%)

09:13
07/23/18
07/23
09:13
07/23/18
09:13
Hot Stocks
Halliburton says activity improved in all geographic markets in Q2 »

Says mindful of of impact…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

09:13
07/23/18
07/23
09:13
07/23/18
09:13
General news
Trump is 'very happy,' says 'Japan is happy, all of Asia is happy' »

President Trump just…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.